Torrent Capital Ltd., (TSXV: TORR), (“Torrent”) announces it has appointed Eric Thompson as Chief Financial Officer effective August 1, 2025, upon the retirement of Rob Randall. Mr. Randall’s retirement comes after a 40-year career including the past nine years as Torrent’s CFO.
Fortune Bay Corp. (TSXV: FOR) (FWB: 5QN) (OTCQB: FTBYF) (“Fortune Bay” or the “Company”) is pleased to announce that it has entered into a definitive option agreement (the “Agreement”), dated July 25, 2025, with Neu Horizon Uranium Limited ACN 653 749 145 (the “Optionee”), a private Australian arms-length party. Pursuant to the Agreement, the Optionee will be granted the option (the “Option”) to acquire an eighty percent interest in The Woods Uranium Projects (“The Woods” or the “Projects”) located on the northern margin of the Athabasca Basin, Saskatchewan (Figure 1).
Fortune Bay Corp. (TSXV: FOR) (FWB: 5QN) (OTCQB: FTBYF) (“Fortune Bay” or the “Company”) is pleased to announce plans to advance its 100% owned Goldfields Project (“Goldfields” or the “Project”) in Saskatchewan, Canada, by completing environmental baseline studies and initiating community engagement through the second half of 2025. Building on extensive historical datasets, the 2025 environmental baseline studies have been designed to establish a foundation for regulatory approvals advancement in 2026.
Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company”, “Sona”) an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, announces that a first dosing has been achieved in the previously announced early feasibility study of its Targeted Hyperthermia Therapy (“THT”) cancer treatment.
Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company”, “Sona”), an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, announces that it has received ethics committee approval to proceed with its previously announced early feasibility study of its Targeted Hyperthermia Therapy (“THT”) cancer treatment.
Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company”, “Sona”) an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, today announced that it has entered into a clinical trial agreement for an early feasibility study clinical trial of its Targeted Hyperthermia Therapy (“THT”). Sona has engaged Bradford Hill Investigacion Clinica (“Bradford Hill”) in Santiago, Chile for a study of Sona’s THT treatment for up to ten patients with advanced melanoma.
Fortune Bay Corp. (TSXV: FOR) (FWB: 5QN) (OTCQB: FTBYF) (“Fortune Bay” or the “Company”) is pleased to announce that it has signed a letter of intent (the “LOI”) with Neu Horizon Uranium Limited ACN 653 749 145 (the “Optionee”), a private Australian arms-length party. Pursuant to the LOI, the Optionee will be granted the option (the “Option”) to acquire an eighty percent interest in The Woods Uranium Projects (“The Woods” or the “Projects”) located on the northern margin of the Athabasca Basin, Saskatchewan (Figure 1).
Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company”, “Sona”) is pleased to announce positive results from a required preclinical safety study evaluating for toxicity issues when animals are injected with its proprietary gold nanorods, conducted by CBSET, Inc.
Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company”, “Sona”) is pleased to announce the successful completion of bacterial endotoxin testing (“BET”) on Sona’s uniquely biocompatible gold nanorods using the Limulus Amebocyte Lysate (“LAL”) method at a leading global provider of laboratory testing and expert advisory services for MedTech and pharmaceutical companies based in the US.
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys”) and Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (“Sona”) announce today that they have entered into a Research Agreement (“Agreement”) to collaborate on the development of new cancer therapeutics based on BioVaxys’ DPX™ Immune Educating Platform (“DPX”) in combination with Sona’s Targeted Hyperthermia Therapy™ (“THT”), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The heat for THT is delivered to tumors using infrared light that is absorbed by Sona’s proprietary biocompatible Gold Nanorod (“GNR”) technology which elicits a strong immune response.